Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | HSD17B13 | Q7Z5P4 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25431886 | 0.88 | NPBWR1 (0.42) | GRM2HPGDTSHRNPBWR1MEN1 | |
| SCHEMBL31227425 | 0.86 | HPGD (0.43) | GRM2HPGDTSHRNPBWR1MEN1 | |
| SCHEMBL31501594 | 0.77 | HSD17B13 (0.46) | HPGDTSHRNPBWR1CNR2HSD17B13 | |
| SCHEMBL30482328 | 0.75 | RORC (0.40) | GRM2HPGDTSHRNPBWR1MEN1 | |
| SCHEMBL30482284 | 0.74 | NPBWR1 (0.42) | HPGDTSHRNPBWR1MEN1KMT2A | |
| SCHEMBL26230068 | 0.74 | NPBWR1 (0.42) | HPGDTSHRNPBWR1MEN1KMT2A | |
| SCHEMBL31227110 | 0.74 | HSD17B13 (0.69) | HSD17B13 | |
| SCHEMBL31227482 | 0.72 | HSD17B13 (0.74) | HSD17B13 | |
| SCHEMBL31227306 | 0.70 | ADORA2A (0.45) | TDP1HSD17B13 | |
| SCHEMBL25431548 | 0.70 | HSD17B13 (0.51) | NPBWR1TDP1CNR2HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100993-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2025-03-27 | — | — | US | disclosed |
| CN-119032090-A | 2-Substituted thiazole HSD17B13 inhibitors and uses thereof | 伊尼制药公司 | 2024-11-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100993-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | HSD17B1, HSD17B3, HSD17B13 | GRM2 3352/4885HPGD 129/4885TSHR 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.